<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502240</url>
  </required_header>
  <id_info>
    <org_study_id>ALK-CLICaP</org_study_id>
    <nct_id>NCT02502240</nct_id>
  </id_info>
  <brief_title>ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP)</brief_title>
  <official_title>Frequency of ALK Rearrangements in Non Small-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the frequency and clinical characteristics of ALK rearrangements in
      Latin-American countries.

      Latin American countries are heterogeneous in terms of lung cancer incidence, ethnicity, and
      exposure to potential carcinogens. The discovery of the echinoderm microtubule-associated
      protein like 4-anaplastic lymphoma kinase (EML4-ALK) translocation as an oncogenic driver has
      led to the development of novel therapies with activity in vitro and in the clinic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The precise frequency of ALK in Latin American population has not been determined. Studies
      isolated in some Latin American countries like Brazil report a frequency of 3.2%, Argentina
      of 4.2% and Mexico of 9.0% of ALK fusion in a small number with lung cancer. Reliable
      information about ALK frequencies and disparities among ethnic groups is critical. Our study
      pretends to know the frequency and clinical characteristics of ALK rearrangement of Latin
      American patients with NSCLC. Discusses the difficulty of having a single diagnostic test for
      this chromosome abnormality.

      The development of efficient and reliable laboratory test is critical in the selection of
      patients likely to respond to these targeted agents. Currently, the current gold standard for
      testing for EML4-ALK translocation is fluorescent in situ hybridization (FISH) for selecting
      patients for ALK-tyrosine kinase inhibitors (TKI) therapy according to the United States Food
      and Drug Administration (FDA). But, an important aspect is the amount of available tumor
      present in a determined sample, given the labor-intensive nature and cost of the test, there
      has been interest in validating other screening and diagnostic tools. Recent evidence
      suggests that ALK Immunohistochemistry (IHC) instruments globally protocols, can be very
      effective in the detection of ALK rearrangement in NSCLC (ALK+) tumors expressing the fusion
      ALK protein.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Anaplastic Lymphoma Kinase (ALK) tumor rearrangement status in Non-Small Cell Lung Cancer (NSCLC) patients</measure>
    <time_frame>1 year</time_frame>
    <description>Positive or negative status. Evaluated by three diagnostic methods: (1) fluorescence in situ hybridization (FISH), (2) immunohistochemistry (IHC) and (3) real-time polymerase chain reaction (RT-qPCR).</description>
  </primary_outcome>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Both: both female and male participants are being studied Analysis of the ALK translocation
        was done either by FISH, IHC, or both, with an adequate amount of cancer cells.
        Demographic, clinical and pathological data was obtained from patients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed lung cancer and tissue availability for ALK analysis.

        Exclusion Criteria:

          -  Not lung cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Gerardo Arrieta Rodriguez, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerología Mexico city</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oscar Gerardo Arrieta Rodriguez, MD MSc</last_name>
    <phone>+52 55 6280400</phone>
    <phone_ext>37045</phone_ext>
    <email>ogarrieta@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrés Felipe Cardona, MD MSc PhD.</last_name>
    <phone>+571 6190052</phone>
    <email>a_cardonaz@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute of Mexico</name>
      <address>
        <city>Mexico city</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar G Arrieta, MD M Sc.</last_name>
      <phone>56 28 04 00</phone>
      <phone_ext>353</phone_ext>
      <email>ogar@unam.mx</email>
    </contact>
    <contact_backup>
      <last_name>Graciela Cruz Rico, M Sc.</last_name>
      <phone>5528880264</phone>
      <email>gracielacr@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Oscar G Arrieta, Oncologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008 Oct 15;14(20):6618-24. doi: 10.1158/1078-0432.CCR-08-1018.</citation>
    <PMID>18927303</PMID>
  </reference>
  <reference>
    <citation>Lopes LF, Bacchi CE. Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. Clinics (Sao Paulo). 2012 Jul;67(7):845-7.</citation>
    <PMID>22892933</PMID>
  </reference>
  <reference>
    <citation>Arrieta O, Cardona AF, Martín C, Más-López L, Corrales-Rodríguez L, Bramuglia G, Castillo-Fernandez O, Meyerson M, Amieva-Rivera E, Campos-Parra AD, Carranza H, Gómez de la Torre JC, Powazniak Y, Aldaco-Sarvide F, Vargas C, Trigo M, Magallanes-Maciel M, Otero J, Sánchez-Reyes R, Cuello M. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015 May;10(5):838-43. doi: 10.1097/JTO.0000000000000481.</citation>
    <PMID>25634006</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Gerardo Arrieta Rodríguez MD</investigator_full_name>
    <investigator_title>Master of biological sciences</investigator_title>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>Latin American</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

